This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Investor Believes Roche Buys Exelixis for Skin-Cancer Drug

Healthcare investor David Miller believes Roche (RHHBY) will likely acquire Exelixis (EXEL) in order to capture the full economics of the cancer drug cobimetinib. The two companies announced positive results from a phase III study of "cobi" in melanoma this morning. 

Miller, a partner at Seattle's Alpine Bioventures hedge fund and long Exelixis, took to Twitter to make his point.

I spoke with him, asking him to elaborate on why he views Exelixis as a Roche takeover target. Miller believes the combination of cobi and Roche's already approved Zelboraf will become the standard of care, first-line therapy for BRAF-mutated melanoma patients. Zelboraf, on its own, is already a $400 million drug worldwide for Roche. The combination with cobi will be priced between $16,000 and $20,000 per month, or a premium to the $16,000 per month GlaxoSmithKline (GSK - Get Report) charges for a similar but inferior combination therapy, Tafinlar and Mekinist, Miller believes. Using the high end of the price range, Miller forecasts combi/Zelboraf in melanoma represents a $600 million to $1 billion revenue opportunity for Roche in the U.S. alone. 

"Roche has been touting the importance of the [cobi/Zelboraf] combination trial for well over a year now. They see the importance of this therapy even if bank analysts don't, and 50% profit share in the U.S. and a low-teens royalty overseas is a lot for Roche to be giving away to Exelixis," says Miller. Historically, Roche has not acquired its cancer drug development partners, but Miller believes Exelixis could prove to be the exception given the large revenue opportunity for cobi.

A lot of investors have been focused on Exelixis' development of cabozantinib in prostate cancer -- and not necessarily in a good way. Results from two phase III prostate cancer studies of "cabo" are expected to be announced this year, and Wall Street (generally speaking) isn't very confident about positive data. 

Miller acknowledges the risk overhang from the cabo prostate cancer studies but believes the drug is real (it's already approved for a form of thyroid cancer) and has a better shot at success in two other, ongoing phase III studies enrolling patients with kidney cancer and liver cancer. Roche may wait to make a bid for Exelixis until after the cabo prostate cancer studies read out results, but before interim results from the kidney cancer study are announced next year. 

How much might Roche bid for Exelixis?

Exelixis' current market cap stands at approximately $680 million. 

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Adam's Tweets

Select the service that is right for you!

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Daily Swing Trade

Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.

Product Features:
  • Daily commentary and coaching on swing trading
  • Technical charts and analysis
Top Rated Stocks Top Rated Funds Top Rated ETFs